MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma
- Liron Zehavi1, 4,
- Hagit Schayek1,
- Jasmine Jacob-Hirsch1,
- Yechezkel Sidi†1, 2, 4Email author,
- Raya Leibowitz-Amit†1, 3Email author and
- Dror Avni†1, 2Email author
© Zehavi et al.; licensee BioMed Central. 2015
Received: 10 November 2014
Accepted: 10 March 2015
Published: 26 March 2015
The incidence of cutaneous malignant melanoma continues to rise, and once the disease metastasizes it is almost inevitably fatal. We recently reported that a large miRNAs cluster on human chromosome 14q32, implicated in many types of cancers, is significantly down-regulated in melanoma. miR-377, one of the miRNAs located within this cluster, was studied here.
qRT-pCR was used to quantify miR-377 levels in melanoma cell lines and samples. Melanoma cell lines ectopically expressing miR-377 were generated by stable transfection, mRNA expression was assessed using mRNA arrays and protein expression was assessed by Western blot analysis. Potential targets of miR-377 were identified through luciferase reporter assays. Cellular proliferation, migration and soft-agar colony formation were monitored in control and miR-377-expressing cells using cell biology techniques.
miR-377 is expressed in normal melanocytes but not in melanoma cell lines or samples. Its ectopic stable expression in melanoma cell lines decreased their proliferative and migratory capacity and their colony-forming capability. mRNA arrays of melanoma cells over-expressing miR-377 pointed to several down-regulated mRNAs that have putative binding sites for miR-377 in their 3′UTR, of which both E2F3 and MAP3K7 were found to be direct targets of miR-377.
E2F3, a potent transcriptional inducer of cell-cycle progression, was found to be elevated in melanoma cell lines, but decreased following ectopic expression of miR-377. Ectopic miR-377 also led to a decrease in the activity of a reporter plasmid containing three E2F DNA-binding sites linked to a luciferase cDNA sequence, demonstrating that miR-377 down-regulates E2F3-induced transcription.
MAP3K7 (known as TAK1), a serine/threonine kinase along the MAPK signaling pathway, was over-expressed in melanoma but decreased following ectopic expression of miR-377. MAP3K7 is involved in the activation of NF-κB. MiR-377 over-expression led to decreased activity of a reporter plasmid containing two NF-κB DNA-binding sites and to decreased output along the NF-kB signaling pathway.
Our results suggest that miR-377 is an important negative regulator of E2F and MAP3K7/NF-kB signaling pathway in melanoma cells; it is tempting to speculate that its silencing in melanoma promotes the tumorigenic and metastatic potential of the cells through activation of these pathways.
Cutaneous malignant melanoma is by far the most aggressive, therapy-resistant and deadly form of skin cancer, and its incidence is on the rise . The prognosis for melanoma is good when it is diagnosed early and surgically excised, but prognosis drops significantly when regional lymph nodes are involved and metastatic melanoma is unfortunately rarely curable. Although much progress has been made in understanding the molecular events leading to the initiation and progress of melanoma [2,3], the current therapeutic interventions for metastatic melanoma are not sufficient and only little improvement in survival has overall been made .
MicroRNAs (miRNAs) are small non-coding RNA molecules that are generated within cells and play a role in post-transcriptional gene regulation. MiRNAs play a role in almost any cellular biological function. Aberrant expression of miRNAs was found in cancerous transformation and progression. Several miRNA profiling studies in melanoma were published so far (reviewed in ), but the picture emerging from these works is far from being clear. One of the largest miRNA clusters is located on chromosome 14q32. This chromosomal area is of great developmental importance, exemplified by severe phenotypes associated with altered dosages of the genes within it in mice and humans . The large miRNA cluster within it has been implicated in many types of cancer [7-14].
Previously, we have identified an almost complete silencing of this cluster in melanoma , and began to study the individual effects and targets of several miRNAs from this cluster on melanoma cell lines, focusing on miRNAs whose expression was decreased between benign nevi and melanoma. We already showed that two miRNAs from this cluster, miR-376a and miR-367c, which are significantly down-regulated in melanoma, target the insulin-growth-factor-1 receptor and can decrease the malignant phenotype of melanoma cells upon ectopic expression . Our current work focuses on miR-377, another miRNA transcribed from the 14q32 cluster.
As previously shown by us, treatment of melanoma cell lines with epigenetic modifiers can re-express several miRNAs from this cluster [15,16]. Similarly, miR-377 was also re-expressed when melanoma cells were treated with epigenetic modifiers; whereas miR-377 could not be detected in untreated melanoma cell lines, it was amplified from melanoma cell lines following treatment with a combination of de-methylating agents and histone deacetylase inhibitors (with a threshold cycle of 34–35 in different cell lines), albeit to lower lever than its levels in normal melanocytes (Figure 1C). This result supports the concept that epigenetic modifications take part in the silencing of this miRNA as well.
In order to point out potential mRNA targets of miR-377, mRNA array analysis was performed, comparing miR-377-expressing and control-HTR-expressing mel33B1 and mel-14PA melanoma cell lines. We searched for transcripts whose expression was decreased in the presence of miR-377. The mRNA expression pattern in mel33B1 and mel-14PA cells differs, yet miR-377 has a clear effect on mRNA expression levels in both cells. Using a cut-off of 1.5-fold-change in expression, we found 363 genes whose expression was decreased in miR-377-expressing mel33B1 cells and 110 transcripts whose expression was decreased in miR-377-expressing mel-14PA cells. Ninety seven genes were down regulated in both cells overexpressing miR-377 and 18 were up regulated in both cells over expressing miR-377 (Additional file 1: Figure S1A, and Additional file 2: Table S1). We then used the miRWalk bioinformatics tool (www.umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html) that provides lists of miRNA-predicted targets according to 10 different bioinformatics software. MiRWalk pointed to 2882 predicted targets of miR-377 that appear in at least 4 out of 10 different softwares. When we crossed this list with the list of down regulated mRNAs in miR-377-expressing melanoma cells, we found 4 putative transcripts with miR-377-binding sites: E2F3 (a putative target of miR-377 in 6 out of 10 software), MAP3K7 (in 4 out of 10), KRAS (in 5 out of 10) and CDK6 (in 5 out of 10). The expression level of these 4 mRNAs on the array is provided in Additional file 1: Figure S1B.
E2F3 mRNA and protein levels were higher in melanoma cell lines compared to NHEM (Figure 6C and D respectively). The effect of miR-377 on the expression of E2F3 mRNA and protein was examined by qRT-PCR and WB analysis of cells over-expressing miR-377. When miR-377 was over-expressed in melanoma cells, the level of E2F3 mRNA was almost unchanged (Figure 6E, left). However, the level of E2F3 protein was decreased by about 70% (Figure 6E, right). This suggests that miR-377 regulates E2F3 expression at the post transcriptional level.
We further asked whether miR-377 affects the biochemical activity of E2F3 using a reporter plasmid containing three E2F3 DNA-binding sites linked to a luciferase cDNA sequence (termed E2F3-BS-luciferase) . Cells over-expressing HTR control vector or vector expressing miR-377 were transfected with E2F3-BS-luciferase vector or empty luciferase vector as an internal control. Over-expression of miR-377 reduced the luciferase activity in the E2F3-BS-luciferase transfected cells, implying that miR-377 led to reduced E2F3 activity (Figure 6F).
Mir-377 over-expression in melanoma cells did not alter the level of MAP3K7 mRNA (Figure 7E). The level of MAP3K7 protein, however, was significantly decreased by about 60% (Figure 7F), suggesting that miR-377 regulates MAP3K7 at the post transcriptional level.
Furthermore, functional analysis of the mRNA expression array of cells over-expressing miR-377 showed a fairly consistent correlation between miR-377 expression and regulation of known gene expression signatures of NFKB1A (IκBα) (Figure 8B). This indirectly implies the involvement of miR-377 in the NF-κB pathway as well.
MiR-377 belongs to a large miRNA cluster on chromosome 14q32 whose expression is silenced in melanoma  and in several additional human malignancies including ependymoma , osteosarcoma , neuroblastoma , gastro-intestinal stromal tumors , uterine osteosarcoma , gliomas  and prostate cancer . In fact, this region was already dubbed, several years ago, ‘the largest miRNA tumor suppressor cluster’ . Ectopic expression of miR-377 in melanoma cells significantly decreased their proliferation and migration rates, and led to significant reduction in their ability to form colonies in soft agar, suggesting that miR-377 has tumor suppressor functions as well.
Little is known about miR-377 targets. miR-377 was shown to target FZD4, a gene important for epithelial-to-mesenchymal transition and to affect migration and invasion in prostate cancer cells . A recently published work, in contrast to our current results, showed that miR-377 can target CDK6 . MiR-377 was not shown to target E2F3 until now.
The E2F family of transcription factors controls cell cycle progression. E2F3 is a potent transcriptional inducer of cell-cycle progression and its amplification was strongly associated with invasive tumor phenotype and high tumor grade in a subset of bladder tumors and in prostate cancer [27,28]. It was recently shown that targeting of E2F3 in melanoma cells by miR-203 inhibited cell growth and induced cell cycle arrest and senescence . E2F activity is necessary for the induction of many genes required for S phase progression and Rb inhibits cell cycle progression by repressing the transcriptional activity of E2Fs and their target genes . We found that E2F3, which is over-expressed in melanoma, is a direct target of miR-377 and its activity is regulated by miR-377. E2F1, −2, and -3a proteins are termed “activators” and facilitate cell cycle progression. In contrast, E2F3b has been classified as a repressor E2F, and it negatively controls the cell cycle . E2F3 encodes two protein products; E2F3a and E2F3b, through the use of alternative promoters and different 5′-coding exons. E2F3a and E2F3b share DNA binding, hetero-dimerization and pocket protein binding domains and differ only in their N-termini . Based on the NCBI database, the sequences of the 3′UTR of human E2F3a and E2F3b are the same. The reduction in E2F3 protein levels that was observed following ectopic expression of miR-377 reflects a reduction in the overall levels of both E2F3a and E2F3b, as the antibody used for their detection cannot discriminate between the two isoforms. Indeed, it is likely that miR-377 targets both E2F3a and E2F3b, as their predicted miR-377 binding sites are present in both 3′UTRs. Hurst el al reported that knockdown of both E2F3a and E2F3b in bladder cancer cells induced the most significant anti-proliferative effects compared with knockdown of any one of them alone. Moreover it has been suggested that E2F3b, which is known to negatively control the cell cycle, acts differently when oncogenic stress is present .
Additional miRNAs have been shown to down-regulate E2F3. For example, it was recently shown that targeting E2F3 by miR-203 in melanoma cells inhibited cell growth and induced cell cycle arrest and senescence . MiR-449b was found to play a tumor-suppressive role by down-regulating E2F3 expression and reducing the proliferative ability of colon cancer stem cells . MiR-125b was suggested to suppress the development of bladder cancer by targeting E2F3 . In addition, it has been reported that E2F1, 2 and 3 are targets of miR-34a in colon cancer cells . Taken together, these observations point to the importance of E2F3 as a key player in cancer progression. In agreement with these observations, in our initial miRNAs microarray (described in ), both miR-125b and miR-34a were down-regulated in melanoma cell lines compared to NHEM; miR-203 and miR-449b were not represented on the array (results not shown).
We found that MAP3K7 is an additional target of miR-377. MAP3K7, also known as TAK1 (TGF-β-activated kinase-1), is a serine/threonine kinase member of the mitogen-activated protein kinase kinase kinase (MAP3K) family, which can be rapidly activated in response to TGF-β signal transduction . MAP3K7 is a key regulator of important cellular pathways associated with the growth of cancer cells (e.g. NF-κB, JNK, and p38 signaling), and was recently shown to have a role in proliferation of melanoma cells [22,37]. Inhibition of MAP3K7 activity induces cancer cell death in pancreatic cancer, suggesting that it may be an effective target for cancer treatment . MAP3K7 regulates both nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways that play key roles in development, cell survival, immune response, metabolism, and carcinogenesis. It was recently shown to have a role in proliferation of melanoma cells . Our results corroborate that its levels are elevated in melanoma, and show that miR-377 directly targets it in the post-transcriptional level, leading to a decrease in its protein levels following miR-377 ectopic expression. An additional regulator of MAP3K7 is miR-26b which down-regulates MAP3K7 and inhibits the NF-κB pathway in hepatocellular carcinoma . In agreement, in our initial miRNAs microarray miR-26b was also down-regulated in melanoma cell lines compared to NHEM .
Although the precise function of MAP3K7 remains obscure, our work along with previous works characterize it as a tumor promoter in a similar manner to other members of the MAP3K family . Knockdown of MAP3K7 in breast cancer cells inhibited both cell adhesion and invasion and led to reduction of both the incidence and extent of lung metastasis in a mouse model . Furthermore, inhibition of MAP3K7 activity induces cancer cell death in pancreatic and breast cancers [38,42], suggesting that MAP3K7 may be an effective target for cancer treatment. Recent studies also demonstrate that MAP3K7 is associated with lymphoid malignancies . In contrast, other works point to MAP3K7 as a tumor suppressor; deletion of the MAP3K7 gene is significantly associated with high-grade prostate cancer  and its loss increased proliferation, migration, and invasion in vitro . Deletion of MAP3K7 in mice liver resulted in carcinogenesis . These reports imply that MAP3K7 can have different roles in different systems and suggest the dual functions of MAP3K7 in tumor initiation, progression, and metastasis as either a tumor promoter or suppressor. The specific role is probably context-dependent and cell type-dependent.
MAP3K7 promotes stabilization and activation of NF-κB; MAP3K7 phosphorylates and activates the IKK complex, leading to the phosphorylation, ubiquitination, and degradation of IκBα, which results in release of inhibition and activation of NF-κB. The freed NF-κB trans-locates into the nucleus and activates transcription of multiple genes involved in pathways controlling immune and inflammatory responses, developmental processes, cellular growth and anti-apoptosis . NF-κB has a critical role in development and progression of many human cancers, including melanoma, in which the expression of NF-κB is up-regulated [48,49]. Suppression of MAP3K7 signaling by dominant negative MAP3K7 reduced NF-kB activation in human head and neck squamous cell carcinoma and breast cancer cell lines [50,51]. In melanoma samples NF-κB pathway is up regulated, affecting survival, proliferation, resistance to apoptosis and metastasis . In fact, it has been demonstrated that up-regulation of NF-κB expression is involved in both the progression of melanoma  and the increase in its metastatic potential .
We found that over-expression of miR-377 decreased NF-κB-induced luciferase expression by about 50%, significantly increased the expression of the NF-κB-inhibitor NFKB1A, and decreased the nuclear fraction of NF-kB. Our results, taken together, suggest that miR-377 decreases NF-κB signaling pathway output, probably through targeting MAP3K7. The decrease in proliferation, migration and colony formation in melanoma cells over-expressing miR-377 can be a consequence of the down-regulation in MAP3K7 and in the activity of the NF-κB pathway.
MiRNAs have been suggested to act as master regulators of key cellular pathways. Our work shows that miR-377 is a key regulator of several cardinal pathways in melanoma progression: E2F and MAP3K7/NF-κB, rendering it a potential new therapeutic target in melanoma.
We show here that the expression of miR-377 is completely silenced in melanoma cell lines and samples, and that it directly targets both the transcription factor E2F3 and MAP3K7, a tyrosine kinase along the MAPK pathway, known to be important in the activation of the NF-kB signaling pathway. Ectopic stable over-expression of miR-377 in melanoma cell lines decreased both E2F3 and MAP3K7 protein levels and led to inhibition of proliferation, migration and colony formation. We show that E2F3-induced activity and NF-kB–induced activity are both inhibited in the presence of miR-377, and that miR-377 leads to alterations in the protein levels of both NFKB1A and NF-kB which are in line with decreased output of the NF-kB signaling pathway (Figure 9). It is tempting to speculate that silencing of miR-377 in melanoma unleashes both the E2F3 and NF-kB signaling pathways, promoting the tumorigenic and metastatic potential of the cells.
Materials and methods
Melanoma cell lines were generated directly from metastatic melanoma lesions of patients at the Surgical branch of the NIH (mel526, mel624, mel33B1; [55,56]), or at the ‘Ella institute for melanoma research’ at the Sheba Medical center (mel-14PA, mel15AY) . Their melanocytic origin was verified by qRT-PCR for the melanocyte specific transcript melan-A (Additional file 3: Figure S2). The cell lines were grown in DMEM/RPMI medium supplemented with 10% fetal bovine serum (FBS), 1% Penicillin–Streptomycin (P/S) antibiotics, 1% L-glutamine and 2.5% Hepes solution. All culture medium components were purchased from Biological Industries. Normal human epidermal melanocytes (NHEM, purchased from Promocell) were grown in melanocyte growth medium according to manufacturer’s instructions. NHEM were maintained in culture for up to 5 cycles. All cells were grown in a 5% CO2 incubator at 37°C.
Formalin-fixed-paraffin-embedded (FFPE) samples of 13 benign nevi or 6 primary cutaneous melanoma were obtained from the pathology institute at the Sheba Medical Center. The initial diagnosis of melanoma and the histological type were verified by a pathologist on the hematoxylin-eosin–stained slides. The tumor or nevus was macro-dissected from the slide in cases in which the sample contained normal tissues as well, based on demarcations delineated by the pathologist. All Nevi were benign, intradermal, some with congenital features. The melanoma samples were of superficial spreading histology (except for one nodular melanoma), 3 of which were ulcerated, with thickness varying from 0.3 to 4.3 mm. The study was approved by the ethics committee of Sheba Medical Center and conducted in adherence to the Declaration of Helsinki protocols.
Total RNA was extracted from cell lines using Ambion miRVana™ MiRNA Isolation Kit (Ambion) or Norgen Total RNA Purification Kit (Norgen). Total RNA from 10 sections of 5 μm FFPE tissues was extracted using the Qiagen miRNeasy FFPE kit (Qiagen). Quantity and quality were evaluated using a Nanodrop ND-2000 (Thermo Scientific) with inclusion criteria of A260/A280 ≥ 1.8.
mRNA micro-array experimentation and analyses
mRNA expression profiling was performed using Affymetrix PrimeView oligonucleotide arrays according to the manufacturer’s protocol. Briefly, 500 ng of Total mRNA was used to generate first-strand cDNA by using a T7-linked oligo (dT) primer. After second-strand synthesis, in vitro transcription was performed with biotinylated UTP and CTP (Affymetrix), resulting in approximately 300-fold amplification of RNA. The target cDNA generated from each sample was processed using an Affymetrix GeneChip Instrument System. Spike controls were added to 15 μg fragmented cRNA before O.N. hybridization. Arrays were then washed and stained with streptavidin-phycoerythrin, before being scanned on an Affymetrix GeneChip scanner. The probe sets contained in the Affymetrix PrimeView oligonucleotide arrays were analyzed using RMA algorithm. Hierarchical clustering was performed using Spotfire DecisionSite for Functional Genomics (Somerville).
Treatment with epigenetic modifiers and protein inhibitors
For epigenetic modifications, cells were seeded at 50% confluence 8 hr prior to treatment with 5-Aza-2′-deoxycytidine (5-Aza 10 μM; Sigma) and valproic acid (VPA 1.5 mM; Sigma) or phenylbutyric acid (PBA 3 mM; Sigma). The drugs were continuously administered by replacing the medium every 24 h for 5 days. For pharmacological inhibition on MAP3K7, we used the commercially available inhibitor 5Z-7-oxozeaenol at a concentration of 4 mM.
Quantitative real time PCR
Quantification of miRNAs by TaqMan MiRNAs assays (Applied Biosystems) was carried out as described by the manufacturer. Briefly, 10 ng of template RNA was reverse transcribed using the TaqMan MicroRNA Reverse Transcription Kit and miRNA-specific stem-loop primers. Target miRNA expression was normalized between different samples based on the values of Rnu19, Rnu43 or Rnu48 expression.
Total RNA was reverse transcribed using the Takara PrimeScript™ RT reagent Kit (Takara). Quantification of mRNA was carried out by TaqMan Gene Expression Assay. Target gene expression was normalized between different samples based on the values of Rplp0 expression.
TaqMan probes: MiR-377 - (000566), E2F3 Hs00605457_m1, MAP3K7 Hs01105682_m1.
For non-quantitative RT-PCR, the following primers were used:
Melan-A: F-ACTCTTACACCACGGCTGAA, R-GCTGTCCCGATGATCAAACC. Hb2M: F-TTCTGGCCTGGAGGCTATC, R-TCAGGAAATTTGACTTTCCATTC.
Cloning and plasmids
The fragments of MAP3K7, E2F3, KRAS, and CDK6 3′ UTR containing the miR-377 target site were amplified from genomic DNA (primers details in Table 1), and cloned into a psiCHECK-II plasmid (Promega) downstream of a reporter Synthetic Renilla luciferase gene (hRluc) using Xho1 and Not1 digesting. Firefly luciferase located downstream the 3′UTR fragment served as transfection internal control.
To generate plasmid with one or more mutations in the binding site for miR-377, the seed regions were mutated from GTGTGAA to GATATAA, The E2F3 mRNA has 3 putative miR-377 binding sites; site-1 at 10–16, site-2 at 951–957 and site-3 at 1251–1257 of the 3′UTR, site-1 was change form, CGTGTGAA to CGATATAA, site −2 was change from TGTGTGAT to TGATATAT and site −3 was change from TGTGTGAG to TGATATAG. All mutation plasmids were generated by using Q5 Site-Directed Mutagenesis Kit (NEB).
pGL4 containing two NF-κB DNA-binding sites linked to a luciferase cDNA sequence gene was kindly given from the Yinon Ben-Neriah lab .
pGL4 containing three E2F DNA-binding sites linked to a luciferase cDNA sequence gene was kindly given from Doron Ginsberg lab .
pRL-CMV Renilla used as an internal control (Promega).
Primers used to amplify the 3′UTR of the marked gene form genomic DNA
F - CCGCTCGAGCTCTGGGACCGTTACATTTTGA
F - CCGCTCGAG CCCTGCTGCAAGAGGACTATC
R - TTTTCCTTTTGCGGCCGCTGTGCCTACCATTGGGTCAG
F – CCGCTCGAGTAAGGCATACTAGTACAAGTGGTAA
R - TTTTCCTTTTGCGGCCGCGAACCTAAGTCACCTTCTTCCT
F - CCGCTCGAG TTTCCTCCTGAGTGGCAAGC
R – TTTTCCTTTTGCGGCCGCTGGAGAGAAAACAGCAGCCT
HEK293T or melanoma cells were seeded in 24-well plates (1 × 105/well) one day before the transfection. Cells were transfected with the indicated vectors for each experiment using Polyethylenimine (PEI, Sigma). 48 h after transfection luciferase activity was determined using the dual luciferase assay system (Promega) according to the manufacturer’s instructions.
Generation of stable melanoma cell lines
Cells were transfected with purified DNA plasmids with the Lipofectamine™ 2000 Transfection Reagent (Invitrogen) according to the manufacturer protocol. 24 h after transfection, Blasticidin antibiotic (10 μg/ml, InvivoGen) was added to the cells for selection. Following selection, the stable ectopic expression of miRNAs was repeatedly assessed using qRT-PCR.
Determination of protein expression level by western blotting (WB)
Whole cell lysates were prepared in cell lysis buffer (50 mM Tis-Hcl, 150 mM NaCL, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40) and supernatants collected by centrifugation. The protein concentration was measured using the Bradford assay (Bio-Rad), and 30 μg of each protein sample were denatured in SDS sample buffer and separated on 10-15% SDS–PAGE. Separated proteins were transferred to nitrocellulose membranes and the blots were blocked using 5% skim milk in PBST. Proteins were reacted with the following primary specific antibodies: GAPDH #2118, Cell-Signaling; E2F3 WH0001871M1, and MAP3K7 SAB1406506 Sigma; IκB-α (C-15) #sc-203, NFκB p65 (C-20) #sc-372 (Santa Cruz Biotechnology). Detection was carried out with horse radish peroxidase conjugated to goat anti-mouse IgG (Jackson Immuno-Research Lab), or goat anti-rabbit IgG (Sigma) followed by chemiluminescent reaction (Pierce). Densitometric analysis were done using ImageJ program.
Nuclear/Cytoplasmic Extraction cells was collected with 1 ml of ice-cold phosphate-buffered saline and centrifuged for 5 min at 6000 g. The supernatant was discarded, followed by another short centrifugation. The pellet was suspended in 9 volumes of HL buffer (10 mM HEPES-KOH, pH 7.5, 10 mM KCl, 3 mM MgCl2, 0.05% Nonidet P-40, 1 mM EDTA, pH 8.0) and incubated for 30 min on ice, followed by centrifugation for 5 min at 600 g, 4°C. 8 volumes of supernatant was collected into a new tube containing an equal volume of 2 × GSLB buffer (90 mM HEPES-KOH, pH 7.9, 500 mM KCl, 0.15% Nonidet P-40, 0.2 mM EGTA, pH 8.0, 20% glycerol), and defined as the “cytoplasmic fraction”. The rest of the supernatant was removed, and the pellet was washed with 9 volumes of HL buffer followed by spinning for 5 min at 600 g, 4°C. The pellet was suspended in 1 × GSLB buffer (50 mM HEPES-KOH, pH 7.9, 250 mM KCl, 0.1% Nonidet P-40, 0.1 mM EDTA, pH 8.0, 0.1 mM EGTA, pH 8.0, 10% glycerol), followed by incubation for 30 min on ice. The tubes were then centrifuged for 10 min, maximum speed, at 4°C, and the supernatant was collected into a new tube, and defined as the “nuclear fraction” .
Melanoma cells (5 × 103) were seeded in 96-well plates and viable cell counts were monitored from seeding time (t = 0) to 96 h every 24 h. The cells were fixated with ethanol 70% and stained with crystal violet 0.1%. The color was extracted using 1% triton x-100 and absorption was read at 550 nm.
Melanoma cells (2 × 105) were seeded in the upper wells of a Transwell migration system on ThinCertsTM inserts with 8-μm membranes (Greiner-bio-one) in DMEM supplemented with 0.1% FBS. The lower well contained the same medium with 10% FBS. After 24 h of incubation, the upper well content, which contained non-migrating cells, was vigorously removed using cotton swabs. The cells that migrated through the membranes were fixated with 70% cold Ethanol, stained with crystal violet 0.1% and photographed using the light microscope.
Melanoma cells were seeded in the xCELLigence DP system (Roche Diagnostics GmbH) and incubated for 1–5 days. The xCELLigence system allows for label-free and dynamic monitoring of cellular phenotypic changes in real time using impedance as readout. The system measures electrical impedance across inter-digitated micro-electrodes integrated on the bottom of tissue culture E-Plates which is then displayed as cell index (CI). Data were collected every 20 min automatically by the analyzer as described in . For verification, a cellular growth curve was also obtained in parallel using the crystal violet technique described above. For monitoring migration, cells were seeded in the upper chamber in the normal culture medium of the respective cell line with 0.1% FBS. This upper chamber was then placed on the lower part of the CIM-device containing growth medium supplemented with 10% FBS as an attractant. Migration of the cells was followed for 24 h by tracking changes of the impedance signal in a CIM-plate measured on the opposing side of the membrane as described in .
Soft agar assay
5 × 103 cells were suspended in media containing 0.3% Select agar (Noble agar, DIFCO) and plated on a bottom layer of media containing 1% Select agar [2% agar was melted in a microwave oven, mixed 1:1 with medium (×2 DMEM medium with 20% FCS, 2% P/S mixture and 2% glutamine)] in a 96-well plate. To enable colony formation plates were incubated at 37°C for 3 weeks. Next, growth medium was removed and colonies were stained with crystal violet 0.1%. Colonies were visualized by light microscopy and were photographed at 5× magnification.
Each experiment was performed in triplicate. Statistical significance was determined using the Student’s t-test or using two-way ANOVA. For a single comparison, a p-value < 0.05 was considered to be statistically significant.
The study was supported by the ‘Morasha’ program of the Israel Science Foundation (grant No. 1499/09) and the ‘Stewart Rahr – MRA Young Investigator Award’ grant (R.L-A). This work was also supported by the Israel Ministry of Health research grant number 4898 (D.A).
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.PubMedView ArticleGoogle Scholar
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.PubMed CentralPubMedView ArticleGoogle Scholar
- Robert C, Thomas L, Bondarenko I, O’Day S, DJ M, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.PubMedView ArticleGoogle Scholar
- Berrocal A, Cabanas L, Espinosa E, Fernandez-de-Misa R, Martin-Algarra S, Martinez-Cedres JC, et al. Melanoma: diagnosis, staging, and treatment. Consensus group recommendations. Adv Ther. 2014;31:945–60.PubMedView ArticleGoogle Scholar
- Leibowitz-Amit R, Sidi Y, Avni D. Aberrations in the micro-RNA biogenesis machinery and the emerging roles of micro-RNAs in the pathogenesis of cutaneous malignant melanoma. Pigment Cell Melanoma Res. 2012;25:740–57.PubMedView ArticleGoogle Scholar
- da Rocha ST, Edwards CA, Ito M, Ogata T, Ferguson-Smith AC. Genomic imprinting at the mammalian Dlk1-Dio3 domain. Trends Genet. 2008;24:306–16.PubMedView ArticleGoogle Scholar
- Arribas AJ, Gomez-Abad C, Sanchez-Beato M, Martinez N, Dilisio L, Casado F, et al. Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. Mod Pathol. 2013;26:889–901.PubMedView ArticleGoogle Scholar
- Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One. 2011;6:e25114.PubMed CentralPubMedView ArticleGoogle Scholar
- Devor EJ, DE Mik JN, Ramachandran S, Goodheart MJ, Leslie KK. Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma. Exp Ther Med. 2012;3:677–82.PubMed CentralPubMedGoogle Scholar
- Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ, et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2014;33:5173–82.PubMedView ArticleGoogle Scholar
- Gattolliat CH, Thomas L, Ciafre SA, Meurice G, Le Teuff G, Job B, et al. Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br J Cancer. 2011;105:1352–61.PubMed CentralPubMedView ArticleGoogle Scholar
- Haller F, von Heydebreck A, Zhang JD, Gunawan B, Langer C, Ramadori G, et al. Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31. J Pathol. 2010;220:71–86.PubMedView ArticleGoogle Scholar
- Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA, et al. Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol. 2010;12:422–33.PubMed CentralPubMedView ArticleGoogle Scholar
- Thayanithy V, Sarver AL, Kartha RV, Li L, Angstadt AY, Breen M, et al. Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone. 2012;50:171–81.PubMed CentralPubMedView ArticleGoogle Scholar
- Zehavi L, Avraham R, Barzilai A, Bar-Ilan D, Navon R, Sidi Y, et al. Silencing of a large micro-RNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. Mol Cancer. 2012;11:44.PubMed CentralPubMedView ArticleGoogle Scholar
- Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006;9:435–43.PubMedView ArticleGoogle Scholar
- Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006;124:1169–81.PubMedView ArticleGoogle Scholar
- Ke N, Wang X, Xu X, Abassi YA. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol Biol. 2011;740:33–43.PubMedView ArticleGoogle Scholar
- Greiner M, Kreutzer B, Jung V, Grobholz R, Hasenfus A, Stohr RF, et al. Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells. Int J Cancer. 2011;128:2284–95.PubMedView ArticleGoogle Scholar
- Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–5.PubMedView ArticleGoogle Scholar
- Lindeman GJ, Gaubatz S, Livingston DM, Ginsberg D. The subcellular localization of E2F-4 is cell-cycle dependent. Proc Natl Acad Sci U S A. 1997;94:5095–100.PubMed CentralPubMedView ArticleGoogle Scholar
- Roh YS, Song J, Seki E. TAK1 regulates hepatic cell survival and carcinogenesis. J Gastroenterol. 2014;49:185–94.PubMed CentralPubMedView ArticleGoogle Scholar
- Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 1987;326:711–3.PubMedView ArticleGoogle Scholar
- Fan Y, Cheng J, Vasudevan SA, Patel RH, Liang L, Xu X, et al. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy. Apoptosis. 2013;18:1224–34.PubMed CentralPubMedView ArticleGoogle Scholar
- Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ, et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2013.Google Scholar
- Wang L, Shao J, Zhang X, Xu M, Zhao J. microRNA-377 suppresses the proliferation of human osteosarcoma MG-63 cells by targeting CDK6. Tumour Biol. 2015.Google Scholar
- Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene. 2004;23:5871–9.PubMedView ArticleGoogle Scholar
- Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene. 2004;23:5616–23.PubMedView ArticleGoogle Scholar
- Noguchi S, Mori T, Otsuka Y, Yamada N, Yasui Y, Iwasaki J, et al. Anti-oncogenic MicroRNA-203 Induces Senescence by Targeting E2F3 Protein in Human Melanoma Cells. J Biol Chem. 2012;287:11769–77.PubMed CentralPubMedView ArticleGoogle Scholar
- Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene. 2005;24:2810–26.PubMedView ArticleGoogle Scholar
- Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, et al. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol. 2000;20:3626–32.PubMed CentralPubMedView ArticleGoogle Scholar
- Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene. 2008;27:2716–27.PubMed CentralPubMedView ArticleGoogle Scholar
- Fang Y, Gu X, Li Z, Xiang J, Chen Z. miR-449b inhibits the proliferation of SW1116 colon cancer stem cells through downregulation of CCND1 and E2F3 expression. Oncol Rep. 2013;30:399–406.PubMedGoogle Scholar
- Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer. 2011;128:1758–69.PubMedView ArticleGoogle Scholar
- Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A. 2007;104:15472–7.PubMed CentralPubMedView ArticleGoogle Scholar
- Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science. 1995;270:2008–11.PubMedView ArticleGoogle Scholar
- Schonherr M, Bhattacharya A, Kottek T, Szymczak S, Koberle M, Wickenhauser C, et al. Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis. Pigment Cell Melanoma Res. 2014;27:418–30.PubMedView ArticleGoogle Scholar
- Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst. 2011;103:1190–204.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhao N, Wang R, Zhou L, Zhu Y, Gong J, Zhuang SM. MicroRNA-26b suppresses the NF-kappaB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer. 2014;13:35.PubMed CentralPubMedView ArticleGoogle Scholar
- Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802;2010:396–405.Google Scholar
- Ray DM, Myers PH, Painter JT, Hoenerhoff MJ, Olden K, Roberts JD. Inhibition of transforming growth factor-beta-activated kinase-1 blocks cancer cell adhesion, invasion, and metastasis. Br J Cancer. 2012;107:129–36.PubMed CentralPubMedView ArticleGoogle Scholar
- Martin SE, Wu ZH, Gehlhaus K, Jones TL, Zhang YW, Guha R, et al. RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors. Curr Cancer Drug Targets. 2011;11:976–86.PubMed CentralPubMedView ArticleGoogle Scholar
- Buglio D, Palakurthi S, Byth K, Vega F, Toader D, Saeh J, et al. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood. 2012;120:347–55.PubMed CentralPubMedView ArticleGoogle Scholar
- Liu W, Chang BL, Cramer S, Koty PP, Li T, Sun J, et al. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res. 2007;13:5028–33.PubMedView ArticleGoogle Scholar
- Wu M, Shi L, Cimic A, Romero L, Sui G, Lees CJ, et al. Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res. 2012;72:2833–43.PubMed CentralPubMedView ArticleGoogle Scholar
- Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K, et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci U S A. 2010;107:844–9.PubMed CentralPubMedView ArticleGoogle Scholar
- Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621–63.PubMedView ArticleGoogle Scholar
- Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.PubMedView ArticleGoogle Scholar
- McNulty SE, del Rosario R, Cen D, Meyskens Jr FL, Yang S. Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res. 2004;17:173–80.PubMedView ArticleGoogle Scholar
- Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lin XL, Darnay BG, et al. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene. 2007;26:1385–97.PubMedView ArticleGoogle Scholar
- Safina A, Ren MQ, Vandette E, Bakin AV. TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene. 2008;27:1198–207.PubMedView ArticleGoogle Scholar
- Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA. NF-kappaB as potential target in the treatment of melanoma. J Transl Med. 2012;10:53.PubMed CentralPubMedView ArticleGoogle Scholar
- Kashani-Sabet M, Shaikh L, Miller 3rd JR, Nosrati M, Ferreira CM, Debs RJ, et al. NF-kappa B in the vascular progression of melanoma. J Clin Oncol. 2004;22:617–23.PubMedView ArticleGoogle Scholar
- Kashani-Sabet M, Liu Y, Fong S, Desprez PY, Liu S, Tu G, et al. Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci U S A. 2002;99:3878–83.PubMed CentralPubMedView ArticleGoogle Scholar
- Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol. 1995;25:340–7.PubMedView ArticleGoogle Scholar
- Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88:100–8.PubMed CentralPubMedView ArticleGoogle Scholar
- Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser MJ, et al. Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immunother. 2010;59:215–30.PubMedView ArticleGoogle Scholar
- Scheinman EJ, Avni O. Transcriptional regulation of GATA3 in T helper cells by the integrated activities of transcription factors downstream of the interleukin-4 receptor and T cell receptor. J Biol Chem. 2009;284:3037–48.PubMedView ArticleGoogle Scholar
- Solly K, Wang X, Xu X, Strulovici B, Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol. 2004;2:363–72.PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.